Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells

Yong Weon Yi; Hyo Jin Kang; Hee Jeong Kim; Yali Kong; Milton M. Brown; Insoo Bae

doi:10.18632/oncotarget.1070

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells

Yong Weon Yi, Hyo Jin Kang, Hee Jeong Kim, Yali Kong, Milton M. Brown and Insoo Bae _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2013; 4:984-994. https://doi.org/10.18632/oncotarget.1070

Metrics: PDF 3041 views | HTML 4208 views | ?

Abstract

Yong Weon Yi1,*, Hyo Jin Kang1,*, Hee Jeong Kim1, Yali Kong3, Milton L. Brown3 and Insoo Bae1,2,3

1 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

2 Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

3 Center for Drug Discovery, Georgetown University, Washington, DC

* These authors contributed equally

Correspondence:

Milton L. Brown, email:

Insoo Bae, email:

Keywords: mutant p53 (mtp53), deacetylation, SIRT1, activator, triple-negative breast cancer (TNBC)

Received: May 31, 2013 Accepted: June 20, 2013 Published: July 5, 2013

Abstract

Many types of mutations in tumor suppressor p53 are oncogenic through gain-of-function. Therefore, targeting mutant p53 (mtp53) is a promising therapeutic approach to fight against many types of cancers. We report here a small molecule compound YK-3-237 that reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells carrying mtp53. YK-3-237 activates SIRT1 enzyme activities in vitro and deacetylation of both mtp53 and wild type p53 (WTp53) in a SIRT1-dependent manner. Deacetylation of mtp53 resulted in depletion of mtp53 protein level and up-regulated the expression of WTp53-target genes, PUMA and NOXA. YK-3-237 also induces PARP-dependent apoptotic cell death and arrests the cell cycle at G2/M phase in mtp53 TNBC cells. Taken together, our data suggest that targeting acetylation of mtp53 is a potential target to treat human cancers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1070

Publication Alerts

Research Papers:

Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells

Abstract